SCHEMBL6925320

SCHEMBL6925320

COc1ccc2[nH]c3c(c2c1)C(=O)CCC3

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.70
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 6/20 0.51
HSD17B10 Q99714 4/20 0.51
MAPT P10636 4/20 0.51
TSHR P16473 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
GFER P55789 1/20 0.51
CYP1A2 P05177 2/20 0.50
CYP2D6 P10635 2/20 0.50
ALOX15 P16050 2/20 0.50
LMNA P02545 2/20 0.50
THRB P10828 1/20 0.50
NFKB1 P19838 1/20 0.50
RECQL P46063 1/20 0.50
PMP22 Q01453 1/20 0.50
PARP1 P09874 1/20 0.49
HPGD P15428 4/20 0.49
HTR6 P50406 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4104903 0.89 KDR (0.55) KDRALDH1A1KDM4EHSD17B10MAPT
SCHEMBL2303878 0.81 ALDH1A1 (0.60) KDRALDH1A1KDM4EHSD17B10MAPT
SCHEMBL4279959 0.79 LMNA (0.67) KDRALDH1A1KDM4EHSD17B10MAPT
SCHEMBL31451663 0.79 KDR (0.85) KDRALDH1A1KDM4EHSD17B10MAPT
SCHEMBL9672176 0.78 MAOB (0.55) ALDH1A1KDM4ELMNAPOLBTDP1
SCHEMBL21758537 0.78 KDR (0.53) KDRALDH1A1KDM4EHSD17B10MAPT
SCHEMBL4025232 0.78 MAPT (0.62) KDRALDH1A1KDM4EHSD17B10MAPT
SCHEMBL6921570 0.78 DYRK1A (0.46) KDRALDH1A1KDM4ELMNAHPGD
SCHEMBL2301312 0.78 LMNA (0.60) KDRALDH1A1KDM4EHSD17B10MEN1
SCHEMBL12284690 0.77 HSD17B10 (0.63) KDRALDH1A1KDM4EHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US disclosed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP disclosed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO disclosed
US-4725615-A SELECTIVE FOR \"NEURONAL\" 5-HYDROXYTRYPTAMINE RECEPTORS; NERVOUS SYSTEM DISORDERS GLAXO GROUP LIMITED 1988-02-16 US disclosed
EP-0219193-A1 Tetrahydrocarbazolone derivatives, processes for their preparation and pharmaceutical compositions containing them GLAXO GROUP LIMITED (GB) 1987-04-22 EP disclosed